Gliclazide
From Wikipedia, the free encyclopedia
 |
|
|
Gliclazide
|
|
| Systematic (IUPAC) name | |
| 3-(7-azabicyclo[3.3.0]oct-7-yl)- 1-(4-methylphenyl)sulfonyl-urea |
|
| Identifiers | |
| CAS number | 21187-98-4 |
| ATC code | A10BB09 |
| PubChem | 3475 |
| DrugBank | APRD00460 |
| Chemical data | |
| Formula | C15H21N3O3S |
| Mol. weight | 323.412 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Gliclazide is an oral hypoglycemic (anti-diabetic drug) and is classified as a sulfonylurea. It is marketed as Diamicron MR®.
Contents |
[edit] Form and Composition:
Each modified-release tablet contains 30 mg of gliclazide.
[edit] Indication:
Type 2 diabetes.
[edit] Dosage:
30 to 120 mg depending on response, once daily with breakfast, including in elderly patients or those with mild-to-moderate renal failure
[edit] Properties:
Hypoglycemic sulfonylurea, restoring first peak of insulin secretion, increasing insulin sensitivity. Glycemia-independent hemovascular effects, antioxidant effect. No active circulating metabolites.
[edit] Contraindications:
type 1 diabetes, hypersensitivity to sulfonylureas, severe renal or hepatic failure, pregnancy and lactation, miconazole coprescription.
[edit] Interactions:
Hyperglycemic action may be caused by danazol, chlorpromazine, glucocorticoids, progestogens, ß-2 agonists. Its hypoglycemic action may be potentiated by phenylbutazone, alcohol, fluconazole, ß-blockers, possibly ACE inhibitors.
[edit] Adverse effects:
Hypoglycemia, gastrointestinal disturbance (reported), skin reactions (rare), hematological disorders (rare), hepatic enzyme rises (exceptional).
[edit] Overdosage:
Possible severe hypoglycemia requiring urgent IV glucose and monitoring.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
